ClinicalTrials.gg
Not yet recruitingNCT07144241Updated Aug 27, 2025

Mesenchymal Stromal/Stem Cells-Derived Exosomes (MSC-Exos) Therapy for Type 2 Diabetes Mellitus Patients

A Phase 2 interventional study of Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy and Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy in Type 2 Diabetes Mellitus, sponsored by Indonesia University. Not yet recruiting at 1 site in Indonesia. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Indonesia University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Diabetes Mellitus, Type 2 by Indonesia University — 3 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Indonesia University.

Planned enrollment
7th of 12
50 · median 55
Started
2025
with 1 other
Phase 2
2 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Diabetes Mellitus, Type 2 by Indonesia University, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 2, and was the 13th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 13 studies in Diabetes Mellitus, Type 2 by Indonesia University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes Mellitus, Type 2 by Indonesia University, or all of them as a file.
02

Study summary

This is an open-label randomized controlled trial with a pre-and-post-test control group design to evaluate the effect of Mesenchymal Stromal/Stem Cells-Derived Exosomes (MSC-Exos) as an adjunctive therapy on glycemic control and clinical outcomes in patients with Type 2 Diabetes Mellitus (T2DM). The study aims to determine if the addition of exosome therapy to standard care can improve glycemic parameters (fasting blood glucose, 2-hour postprandial glucose, HbA1c, and C-peptide), quality of life, and inflammatory biomarkers (IL-6, IL-10, D-dimer, and CRP). The study will involve 50 subjects, randomly allocated into two groups: an intervention group and a control group. The intervention group will receive standard T2DM therapy plus a combination of exosomes (1 vial Exo-HWS + 1 vial Exo-HUVEC). The control group will receive standard T2DM therapy plus 1 vial Exo-HWS. The study duration is from June to December 2025.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • DMT2
  • Mesenchymal Stromal/Stem Cells-Derived Exosomes
  • Glycemic Profile
  • Quality of Life
  • Inflammatory Biomarkers
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with Type 2 Diabetes Mellitus.
  • Patients aged 40 to 65 years.
  • Patients who are willing to participate in the study and sign the form after receiving a detailed explanation of the research procedure.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe comorbidities that could affect the immune response, such as diseases, , and severe infections.
  • Patients currently undergoing anticoagulant therapy.
  • Patients currently undergoing therapy.
  • Pregnant women, as the effects of exosome therapy on them have not been sufficiently studied.
  • Patients with a history of severe allergies to components of the exosome therapy.
  • Patients with CKD (Chronic Kidney Disease) on HD (Hemodialysis).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Group 1: Intervention Group

    Receives standard therapy for Diabetes Mellitus (DM) plus a combination of exosomes (1 vial Exo-HWS + 1 vial Exo-HUVEC). Administered as a monthly intravenous bolus injection for three months

    Biological: Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy

  • Placebo comparator
    Group 2: Control Group

    Receives standard therapy for DM plus 1 vial of Exo-HWS. Administered as a monthly intravenous bolus injection for three months.

    Biological: Mesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy

Interventions

  • BiologicalMesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS + 1 vial Exo-HUVEC) Therapy

    The intervention group will receive standard DM therapy plus an exosome combination of 1 vial Exo-HWS + 1 vial Exo-HUVEC, administered monthly for three months via intravenous bolus injection.

  • BiologicalMesenchymal Stromal/Stem Cells-Derived Exosomes (Exo-HWS ) Therapy

    The control group will receive standard DM therapy plus 1 vial Exo-HWS, administered monthly for three months via intravenous bolus injection.

06

What researchers measure

Primary outcomes

  1. Fasting Blood Glucose (FBG)

    Change in FBG levels from baseline to the end of the third month. Unit of Measurement: mg/dL

    Time frame: Baseline (Day 0) and End of the 3rd Month

  2. 2-Hour Postprandial Glucose

    Change in 2-hour postprandial glucose levels from baseline to the end of the third month. Unit of Measurement: mg/dL

    Time frame: Baseline (Day 0) and End of the 3rd Month

  3. HbA1c

    Change in HbA1c levels from baseline to the end of the third month. Unit of Measurement: %

    Time frame: Baseline (Day 0) and End of the 3rd Month

  4. C-peptide

    Change in C-peptide levels from baseline to the end of the third month. Unit of Measurement: ng/m

    Time frame: Baseline (Day 0) and End of the 3rd Month

Secondary outcomes

  1. Quality of Life using DQoL

    Change in quality of life scores as measured by the Diabetes Quality of Life (DQoL) questionnaire from baseline to the end of the third month. Unit of Measurement: Score

    Time frame: Baseline (Day 0) and End of the 3rd Month

  2. IL-6

    Change in Interleukin-6 (IL-6) levels from baseline to the end of the third month. Unit of Measurement: mg/L

    Time frame: Baseline (Day 0) and End of the 3rd Month

  3. IL-10

    Change in Interleukin-10 (IL-10) levels from baseline to the end of the third month. Unit of Measurement: mg/L

    Time frame: Baseline (Day 0) and End of the 3rd Month

  4. D-dimer

    Change in D-dimer levels from baseline to the end of the third month. Unit of Measurement: ng/mL

    Time frame: Baseline (Day 0) and End of the 3rd Month

  5. CRP

    Change in C-Reactive Protein (CRP) levels from baseline to the end of the third month. Unit of Measurement: mg/L

    Time frame: Baseline (Day 0) and End of the 3rd Month

07

Study locations

1 site
  • UNIMUS Hospital
    Semarang, Central Java, Indonesia
08

References and documents

Publications

  • Li CJ, Xiao Y, Sun YC, He WZ, Liu L, Huang M, He C, Huang M, Chen KX, Hou J, Feng X, Su T, Guo Q, Huang Y, Peng H, Yang M, Liu GH, Luo XH. Senescent immune cells release grancalcin to promote skeletal aging. Cell Metab. 2021 Oct 5;33(10):1957-1973.e6. doi: 10.1016/j.cmet.2021.08.009. Epub 2021 Sep 9. PubMed 34614408 ↗
  • Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020 Feb 7;367(6478):eaau6977. doi: 10.1126/science.aau6977. PubMed 32029601 ↗
  • Lai RC, Yeo RW, Lim SK. Mesenchymal stem cell exosomes. Semin Cell Dev Biol. 2015 Apr;40:82-8. doi: 10.1016/j.semcdb.2015.03.001. Epub 2015 Mar 9. PubMed 25765629 ↗
  • Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013 Feb 18;200(4):373-83. doi: 10.1083/jcb.201211138. PubMed 23420871 ↗
  • American Diabetes Association. Standards of Medical Care in Diabetes-2021 Abridged for Primary Care Providers. Clin Diabetes. 2021 Jan;39(1):14-43. doi: 10.2337/cd21-as01. No abstract available. PubMed 33551551 ↗
  • Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besancon S, Bommer C, Esteghamati A, Ogurtsova K, Zhang P, Colagiuri S. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2020 Apr;162:108072. doi: 10.1016/j.diabres.2020.108072. Epub 2020 Feb 13. PubMed 32061820 ↗

Individual participant data

Plan to share: No — There is no explicit plan to share Individual Participant Data (IPD) from this study. The research team's commitment to participant confidentiality is paramount. The informed consent form assures participants that their data and information will be kept confidential and will be used solely for the purpose of the research, education, and scientific development, without disclosing their identity. This approach aligns with the ethical clearance obtained for the study, which emphasizes protecting participant identity.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2025, 3 months later.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 3 months is below that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Aug 27, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jul 1, 2026
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07144241
Responsible party
Yanuar Ardani (Principal Investigator, Indonesia University) — Principal investigator
First posted
Aug 27, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Aug 27, 2025

Study contacts

Dr. dr. Yanuar Ardani, M.Kes, Sp.PD, K-PPM, FINASIM
Contact
dr.yanuardani@gmail.com
085227700340

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion